Portola Pharmaceuticals Lands $60M
South San Francisco-based Portola Pharmaceuticals said yesterday that it has raised $60M in a preferred stock financing. The firm, which is focused on developing therapeutics for cardiovascular and inflammatory disease, said the funding came from D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK BioVentures, along with existing investors. Portola said the funding will be used to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128.
posted on Thursday, July 10, 2008 (Link to more information)
Related companies:
Portola Pharmaceuticals
Related stories:
> Portola Pharmaceuticals Raises $89M
> Portola Pharmaceuticals Gets $70M In Series C
> Third Rock Ventures Raises $426M Fund, Sets Up Shop In San Francisco
> Edison Pharmaceuticals Lands Series E
> Arriva Pharmaceuticals Adds $6M
silicontap.com Home